Treatment Regimen With Bevacizumab Decreases Mean Platelet Volume in Patients With Metastatic Colon Cancer

被引：24
作者：
Mutlu, Hasan [1 ]
Berk, Veli [2 ]
Karaca, Halit [2 ]
Erden, Abdulsamet [3 ]
Aslan, Tuncay [3 ]
Akca, Zeki [4 ]
机构：
[1] Kayseri Educ & Res Hosp, Dept Med Oncol, Kayseri, Turkey
[2] Erciyes Univ, Dept Med Oncol, Kayseri, Turkey
[3] Kayseri Educ & Res Hosp, Dept Internal Med, Kayseri, Turkey
[4] Mersin Govt Hosp, Dept Radiat Oncol, Mersin, Turkey
来源：
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS | 2012年 / 18卷 / 05期
关键词：
bleeding; deep venous thrombosis; platelet dysfunction; RENAL-CELL CARCINOMA; ADVANCED COLORECTAL-CANCER; PHASE-III TRIAL; 1ST-LINE TREATMENT; LUNG-CANCER; DISEASE; PACLITAXEL; ANGIOGENESIS; CARBOPLATIN; OXALIPLATIN;
D O I：
10.1177/1076029611430958
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The risk of thromboemboli is increased in patients with cancer, and this is precipitated by the chemotherapeutic agents. Bevacizumab is an anti-vascular endothelial growth factor monoclonal antibody and has an importance in the treatment of metastatic colon cancer. The association between bevacizumab, which is demonstrated to increase the risk of thromboemboli, and mean platelet volume (MPV), which is a marker of thrombocyte function, has been investigated within study. A total of 74 patients with metastatic colon cancer were included in the study and the levels of platelets (PLTs), MPV, and platecrit (PCT) values were recorded in SPSS 16.0 program both at baseline and at the > third month. There were significant decreases in 3 parameters (PLT, MPV, and PCT) during the treatment period with bevacizumab (P = .009, P = .001, and P = .000, respectively). Unlike cases with thrombosis, there is a significant decrease in MPV in combination treatments with bevacizumab.
引用
收藏
页码：546 / 548
页数：3
相关论文
共 31 条
  • [1] Thromboembolism in cancer patients: Pathogenesis and treatment
    Adess, Matthew
    Eisner, Robert
    Nand, Sucha
    Godwin, John
    Messmore, Harry L., Jr.
    Wehrmacher, William H.
    [J]. CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2006, 12 (03) : 254 - 266
  • [2] Platelet size: Measurement, physiology and vascular disease
    Bath, PMW
    Butterworth, RJ
    [J]. BLOOD COAGULATION & FIBRINOLYSIS, 1996, 7 (02) : 157 - 161
  • [3] Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic oncology group study
    Burger, Robert A.
    Sill, Michael W.
    Monk, Bradley J.
    Greer, Benjamin E.
    Sorosky, Joel I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (33) : 5165 - 5171
  • [4] A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer
    Cheeseman, SL
    Joel, SP
    Chester, JD
    Wilson, G
    Dent, JT
    Richards, FJ
    Seymour, MT
    [J]. BRITISH JOURNAL OF CANCER, 2002, 87 (04) : 393 - 399
  • [5] Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions
    Coppinger, JA
    Cagney, G
    Toomey, S
    Kislinger, T
    Belton, O
    McRedmond, JP
    Cahill, DJ
    Emili, A
    Fitzgerald, DJ
    Maguire, PB
    [J]. BLOOD, 2004, 103 (06) : 2096 - 2104
  • [6] Mechanisms of disease:: Platelet activation and atherothrombosis
    Davi, Giovanni
    Patrono, Carlo
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (24) : 2482 - 2494
  • [7] Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease
    Endler, G
    Klimesch, A
    Sunder-Plassmann, H
    Schillinger, M
    Exner, M
    Mannhalter, C
    Jordanova, N
    Christ, G
    Thalhammer, R
    Huber, K
    Sunder-Plassmann, R
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2002, 117 (02) : 399 - 404
  • [8] Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
    Escudier, Bernard
    Pluzanska, Anna
    Koralewski, Piotr
    Ravaud, Alain
    Bracarda, Sergio
    Szczylik, Cezary
    Chevreau, Christine
    Filipek, Marek
    Melichar, Bohuslav
    Bajetta, Emilio
    Gorbunova, Vera
    Bay, Jacques-Olivier
    Bodrogi, Istvan
    Jagiello-Gruszfeld, Agnieszka
    Moore, Nicola
    [J]. LANCET, 2007, 370 (9605) : 2103 - 2111
  • [9] Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
    Friedman, Henry S.
    Prados, Michael D.
    Wen, Patrick Y.
    Mikkelsen, Tom
    Schiff, David
    Abrey, Lauren E.
    Yung, W. K. Alfred
    Paleologos, Nina
    Nicholas, Martin K.
    Jensen, Randy
    Vredenburgh, James
    Huang, Jane
    Zheng, Maoxia
    Cloughesy, Timothy
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (28) : 4733 - 4740
  • [10] Fuchs CS, 2007, J CLIN ONCOL, V25, P4779, DOI 10.1200/JCO.2007.11.3357
1234